Resistance remains one of the most significant barriers to optimal treatment outcomes and overall survival for patients across cancer types. Although genetic mutations play a key role in poor therapeutic responses, the gut microbiome may also interfere with critical therapies in the cancer treatment landscape. Studies show that disruptions in gut microbiota are associated with resistance and less favorable responses to immunotherapies.
Drawing of the gut microbiome | Image Credit: © ArtemisDiana – stock.adobe.com
Deeper knowledge of the integral relationship between the gut and cancer therapy is critical for maintaining the integrity and efficacy of agents that have revolutionized cancer treatment over the past few decades. At the 2025 ASCO Annual Meeting, experts discussed the complexity of the gut microbiota and…